Placebo (for ezetimibe)

DRUG2 trials

Sponsors

Sanofi

Conditions

Hypercholesterolemia

Phase 3

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

CompletedNCT01644188

SanofiHypercholesterolemia

Start: 2012-08-31End: 2015-07-31Updated: 2016-08-04

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

CompletedNCT01644474

SanofiHypercholesterolemia

Start: 2012-07-31End: 2013-07-31Updated: 2015-11-06

Related Papers

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

Journal of the American College of Cardiology2017-01-30193 citations

Reductions in Atherogenic Lipids and Major Cardiovascular Events

Circulation2016-10-25128 citations

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

European Heart Journal2015-02-16394 citations

ODYSSEY COMBO II: Alirocumab Significantly Improves Cholesterol Levels in Patients with High CV Risk

MD Conference Express2014-10-01

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.

2014-09-2042 citations

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.

2014-07-02193 citations